MENU
MEDP
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

MEDP stock forecast, quote, news & analysis

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms... Show more

A.I.Advisor
published price charts
MEDP
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for MEDP with price predictions
Oct 13, 2026

MEDP in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 01, 2026

MEDP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 31 cases where MEDP's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 58 cases where MEDP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

MEDP moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDP advanced for three days, in 239 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 197 of 260 cases where MEDP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MEDP as a result. In 55 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 56%.

The Moving Average Convergence Divergence Histogram (MACD) for MEDP turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 38 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 22 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. MEDP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (39.683) is normal, around the industry mean (72.578). P/E Ratio (36.187) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (2.929) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (6.390) is also within normal values, averaging (9.775).

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 20.78B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -4%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 38%. MDXH experienced the highest price growth at 10%, while BIAF experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was -28%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 59
Price Growth Rating: 43
SMR Rating: 78
Profit Risk Rating: 90
Seasonality Score: 20 (-100 ... +100)
MEDP in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 01, 2026